Scientists have engineered tiny biological delivery vehicles that carry a tumor-suppressive microRNA directly into triple-negative breast cancer cells, reporting targeted uptake and anti-tumor effects in laboratory and ex vivo models. The study, published in Cancer Nanotechnology, describes a platform built from small extracellular vesicles derived from HEK293 cells and modified with a targeting peptide called GE11, which binds the epidermal growth factor receptor 1 (EGFR1) found at high levels on many triple-negative breast cancer cells.
Triple-negative breast cancer is among the most aggressive breast cancer subtypes. It lacks expression of the estrogen receptor, the progesterone receptor and human epidermal growth factor receptor 2, the molecular targets that anchor many modern breast cancer therapies. As a result, treatment options remain limited, and the disease carries high metastatic potential and frequent recurrence. These clinical realities drive interest in precision approaches that can attack tumor cells selectively while sparing healthy tissue.
One such approach is microRNA replacement therapy. Tumor-suppressive microRNAs, small RNA molecules that regulate gene expression, can restrain cancer cell behavior when delivered into tumor cells. The researchers focused on miR-204, a microRNA with known tumor-suppressive activity. The central obstacle, however, is delivery: free microRNAs are unstable in biological environments, and efficient, tumor-targeted delivery systems remain a bottleneck for translating the concept into practice.
Small extracellular vesicles, membrane-bound nanoparticles naturally released by cells, have emerged as attractive carriers for this purpose. The authors note that they offer inherent biocompatibility, low immunogenicity and the ability to transport functional nucleic acids. Until now, however, selective vesicle-based delivery platforms aimed specifically at EGFR1-overexpressing triple-negative breast cancer had not been fully explored, according to the study team.
To build their system, the researchers surface-functionalized HEK293-derived small extracellular vesicles with the GE11 peptide, a ligand that targets EGFR1, and loaded the vesicles with miR-204. The engineering steps preserved the vesicles’ physicochemical integrity: the particles retained their structural properties after both peptide conjugation and microRNA incorporation, an important requirement for any candidate nanocarrier.
Functional testing showed that the GE11-functionalized vesicles were taken up more efficiently by EGFR1-overexpressing triple-negative breast cancer cells than by non-TNBC cells, demonstrating the selectivity conferred by the targeting peptide. Once inside the tumor cells, the delivered miR-204 produced measurable anti-tumor effects in vitro: the treatment significantly inhibited TNBC cell proliferation, clonogenic growth, migration and invasion, the key cellular processes that drive tumor expansion and spread.
To understand what the delivered microRNA was doing at the molecular level, the team performed quantitative proteomic profiling. This analysis identified a distinct miR-204-associated molecular signature, revealing a subset of proteins that were downregulated and that are implicated in tumor progression. The findings suggest the delivered microRNA reshapes the protein landscape of treated cells in ways consistent with its tumor-suppressive role.
The platform was also evaluated in an ex vivo model that better approximates tumor architecture than flat cell cultures: three-dimensional TNBC spheroids. In this system, the GE11-engineered, miR-204-loaded vesicles suppressed spheroid growth, providing an additional layer of evidence beyond two-dimensional cell assays. The researchers also reported that the engineered formulation showed excellent biocompatibility without compromising vesicle stability, addressing two common failure points for nanoparticle therapeutics.
The authors conclude that GE11-engineered small extracellular vesicles provide an effective and selective nanocarrier platform for targeted miR-204 delivery in EGFR1-positive triple-negative breast cancer. By combining receptor-mediated targeting with microRNA replacement therapy, the strategy enhances therapeutic specificity and anti-tumor efficacy in the models tested. They emphasize, however, that the work so far rests on in vitro and ex vivo evidence, and they highlight the platform as one that warrants further in vivo evaluation toward precision nanomedicine applications. No human clinical findings are reported in the study.
Subject of Research: Targeted delivery of the tumor-suppressive microRNA miR-204 to EGFR1-positive triple-negative breast cancer cells using GE11-engineered small extracellular vesicles
Article Title: GE11-engineered small extracellular vesicles enable targeted delivery of miR-204 in EGFR1-positive triple-negative breast cancer cells
Article References: Unnikrishnan, K., Jaya, K., Patwardhan, S., Ram Kumar, R. M., & Srinivas, P. (2026). GE11-engineered small extracellular vesicles enable targeted delivery of miR-204 in EGFR1-positive triple-negative breast cancer cells. Cancer Nanotechnology. https://doi.org/10.1186/s12645-026-00433-7
Image Credits: AI Generated
DOI: 10.1186/s12645-026-00433-7
Keywords: triple-negative breast cancer, small extracellular vesicles, GE11 peptide, miR-204, EGFR1, microRNA therapy, nanomedicine, drug delivery, proteomics, tumor spheroids, biocompatibility, GE11-engineered
News Source: Nathaniel Bowman. (October 28, 2026). Engineered vesicles deliver miR-204 to triple-negative breast cancer cells in preclinical tests. Scienmag.
